Fenchem, which has its headquarters and manufacturing base in Nanjing, China, announces the opening of a SAM-e facility in Czech Republic. The new facility offers Europe a source of SAM-e of high quality and safety. With the establishment of Fenchem’s European head office in Czech Republich in 2010, the opening of the Czech plant fits into the overall growth strategy of Fenchemin the area of nutraceuticals for both human and animals.
The SAM-emarket is growing steadily and has proven very robust. Fenchem has begun its SAM-e operation in Europe due to the growing demand locally and the safety concerns of China origin products, as the US and the EU are its target markets.
In 2007 FDA found contaminants in vegetable proteins imported into the United States from China and used as ingredients in pet food. This makes consumer concerned over China-sourced ingredients. Czech production site focuses on supplying high quality SAM-e targeting both pet food and human nutrition market. Fenchem has established a professional management system from raw material purchasing, developing, manufacturing to quality testing, to control all production stages which ensures our customers with ingredients of high quality and safety standards.
Europe has always been an important target market. The operation will enable a rapid response time to local customer orders and supply better services for them. And it is designed to ensure that production capabilities meet increasing customer demands. Final production output of the Czech production site by 2013 is expected to nearly double the current output.
SAM-e is a natural compound found in every human cell and involved in over 35 biochemical processes in the body. It is traditionally sold as a prescription medicationin Europe, and however as dietary supplement in the US in the treatment of many conditions including depression, liver disease and osteoarthritis etc. It is also used as supplement in dogs and cats to preserve and fortify liver function.
Fenchem’s SAMe-wayTMSAM-eis available in two salt forms, Ademetionine 1,4-Butanedisulfonate and Ademetionine Disulfate Tosylate. One prominent advantage of SAMe-way is that the ratio of active ingredient (s,s) isomer is high up to more than 70%, which ensures high bioavailability and cost savings for customers.